Hanmi Pharmaceutical Deals with Sanofi, Janssen

by | Nov 10, 2015 9:30 am | Pharmaceuticals

Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. popped up on the healthcare M&A radar last week with two collaboration announcements. First was an agreement with French drug maker Sanofi (NYSE: SNY) to grant the worldwide license to a yet-to-be developed portfolio of experimental, long-acting diabetes treatments. Sanofi paid an upfront fee of €400 million ($434,820,000) and is eligible for up to €3.5 billion in development, registration and sales milestone, as well as double digit royalties on net sales. The second deal, with Janssen Pharmacticals, Inc. (NYSE: JNJ), was for the rights to oxyntomodulin-based therapies, including Hanmi’s NM12525A. Janssen paid $105... Read More »

Allergan Licenses Dry Eye Treatment

by | Nov 9, 2015 8:32 pm | Pharmaceuticals

Allergan plc (NYSE: AGN) is making inroads in the dry eye disease treatment area, paying $50 million upfront to license Mimetogen Pharmaceuticals’ tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist. Allergan will also fund Phase 3 development of the drug, which has shown the ability to improve patient-reported blurriness and poor vision. The deal bolsters Allergan’s mid- to late-stage pipeline in eye care products. Read More »

Big Deal of the Day: Shire Buys Dyax

by | Nov 3, 2015 6:48 pm | Biotechnology, Pharmaceuticals

Shire plc (NASDAQ: SHPG) is on a buying binge in 2015. After agreeing to be acquired by AbbVie (NYSE: ABBV) for $54.7 billion in July 2014, the deal fell apart in October following the Treasury Department’s revised ruling on foreign domiciles. Shire management turned around and acquired rare disease drug maker NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) in January for $5.2 billion, then added prescription drug maker  Meritage Pharma, Inc. in February for $70 million. After a few months digesting those deals, Shire was back on the acquisition trail in August, paying $300 million for Foresight Biotherapeutics Inc., a clincal stage drug development company. Now it’s agreed to pay... Read More »

Q3:15 Health Care Dollars, vs. Q2:15

by | Nov 2, 2015 8:57 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we gave you the breakdown on how the third quarter of 2015 compared with the second quarter and the same quarter a year ago. Here’s how the dollars broke out, versus those quarters. SectorQ3:15Q2:15ChangeQ3:14Change Services Behavioral Health Care$550,000$190,700188%$335,00064% Home Health & Hospice$241,854$0n/a$410,000-41% Hospitals$2,069,865 $2,059,9000.5%$969,800113% Labs, MRI & Dialysis$826,600$1,507,650-45%$324,000155% Long-Term Care$4,175,656$4,141,9300.8%$9,686,200-57% Managed Care$98,000,000$147,00066566%$0n/a Physician Medical Groups$1,600,000$500,000220%$0n/a Rehabilitation $4,300$734,800-99%$163,450-97% Other Services$1,396,474$16,211,644-91%$1,026,40036%... Read More »

Q3:15 Health Care Deal Volume

by | Oct 26, 2015 9:15 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

We’re just about to publish our third quarter results this week, but wanted to give you a sneak preview of how the third quarter stacks up against Q2:15 and the same quarter a year ago. Here’s the chart. SectorQ3:15 DealsQ2:15 DealsChangeQ3:14 DealsChange Services Behavioral Health Care10667%4150% Home Health & Hospice9650%15-40% Hospitals332438%1974% Labs, MRI & Dialysis16157%8100% Long-Term Care906538%856% Managed Care12850%5140% Physician Medical Groups1522-32%147% Rehabilitation7617%540% Other Services464015%3628% Services subtotal23819224%19125% Technology Biotechnology413421%27%52% eHealth3334-3%34-3% Medical Devices31297%2619% Pharmaceuticals423811%67-37%... Read More »

Q3:15 Health Care M&A, by Spending

by | Oct 19, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we shared our data on health care M&A by sector in the third quarter of 2015. Here’s a look at the same sectors, by share of the dollars spent. If you’ve been following health care M&A at all, you won’t be surprised that the Managed Care sector (health insurers) accounts for about 50% of the $198 billion spent. That total, by the way, is also a new quarterly record. Look for The Health Care M&A Report, Third Quarter, for more in-depth analysis by sector. Read More »